Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
Обзорная статья

More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis

Sandra López‐LeónDrug Development, Novartis Pharmaceuticals, New Jersey, USATalía Wegman-OstroskyInstituto Nacional de Cancerología, Subdirección de Investigación básica, Ciudad de México, MéxicoCarol PerelmanNational Autonomous University of Mexico, SOMEDICyT, RedMPC, MéxicoRosalinda SepúlvedaHarvard T.H. Chan School of Public Health Boston, Massachusetts, USAPaulina A. RebolledoDivison of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USAAngélica CuapioCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institute, Stockholm, SwedenSonia VillapolDepartment of Neuroscience in Neurological Surgery, Weill Cornell Medical College, New York, USA
2021en
ABI

Аннотация

ABSTRACT COVID-19, caused by SARS-CoV-2, can involve sequelae and other medical complications that last weeks to months after initial recovery, which has come to be called Long-COVID or COVID long-haulers. This systematic review and meta-analysis aims to identify studies assessing long-term effects of COVID-19 and estimates the prevalence of each symptom, sign, or laboratory parameter of patients at a post-COVID-19 stage. LitCOVID (PubMed and Medline) and Embase were searched by two independent researchers. All articles with original data for detecting long-term COVID-19 published before 1 st of January 2021 and with a minimum of 100 patients were included. For effects reported in two or more studies, meta-analyses using a random-effects model were performed using the MetaXL software to estimate the pooled prevalence with 95% CI. Heterogeneity was assessed using I 2 statistics. This systematic review followed Preferred Reporting Items for Systematic Reviewers and Meta-analysis (PRISMA) guidelines, although the study protocol was not registered. A total of 18,251 publications were identified, of which 15 met the inclusion criteria. The prevalence of 55 long-term effects was estimated, 21 meta-analyses were performed, and 47,910 patients were included. The follow-up time ranged from 14 to 110 days post-viral infection. The age of the study participants ranged between 17 and 87 years. It was estimated that 80% (95% CI 65-92) of the patients that were infected with SARS-CoV-2 developed one or more long-term symptoms. The five most common symptoms were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnea (24%). All meta-analyses showed medium (n=2) to high heterogeneity (n=13). In order to have a better understanding, future studies need to stratify by sex, age, previous comorbidities, severity of COVID-19 (ranging from asymptomatic to severe), and duration of each symptom. From the clinical perspective, multi-disciplinary teams are crucial to developing preventive measures, rehabilitation techniques, and clinical management strategies with whole-patient perspectives designed to address long COVID-19 care.

Перевод пока недоступен

Идентификаторы

Цитирования и источники

Цитирований: 4Использованных источников: 0